Current approaches in dendritic cell generation and future implications for cancer immunotherapy. - Wikidata - wikimedia - TriplyDB

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

http://www.wikidata.org/entity/Q36822028

about

Dendritic cell-based immunity and vaccination against hepatitis C virus infection Therapeutic cancer vaccines: past, present, and future Dendritic cells derived from pluripotent stem cells: Potential of large scale production Progress in immunotherapy for non-small cell lung cancer Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.In vitro differentiation of dendritic cells in the presence of prostaglandin E2 alters the IL-12/IL-23 balance and promotes differentiation of Th17 cells.Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma CCL21 Cancer Immunotherapy.HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cells CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy Monocyte-derived DC maturation strategies and related pathways: a transcriptional view A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo Fibroblast and T cells conditioned media induce maturation dendritic cell and promote T helper immune response Targeting the tumor microenvironment to enhance antitumor immune responses Cellular-based immunotherapies for patients with glioblastoma multiforme.Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.Early secreted antigenic target of 6-kDa protein of Mycobacterium tuberculosis primes dendritic cells to stimulate Th17 and inhibit Th1 immune responses.The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates.Dendritic cell-based cancer vaccination: quo vadis?Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors.DC vaccination with anti-CD25 treatment leads to long-term immunity against experimental glioma.CD137L-stimulated dendritic cells are more potent than conventional dendritic cells at eliciting cytotoxic T-cell responses.Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification.The evolving role of dendritic cells in cancer therapy.Personalized dendritic cell-based tumor immunotherapy.Immunogenicity of targeted lentivectors.Dendritic cell-based vaccines for the therapy of experimental tumors.Engineering dendritic cells to enhance cancer immunotherapy.Tumor evasion from T cell surveillance.Biological applications of magnetic nanoparticles.Cell-based drug-delivery platforms.Targeting lentiviral vectors for cancer immunotherapy.Dendritic cell-based immunotherapy in mesothelioma.Dendritic cell-based vaccination for renal cell carcinoma: challenges in clinical trials.Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy.mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic.

P2860

Q26828003-D82C8A6F-E811-4FBA-92A7-6CD412E68003 Q26863283-96B361A0-F92D-4457-86CB-A414F4694086 Q26865622-743FA6D6-62EB-4FA1-B085-395869FA385B Q26865725-649853AE-497F-4035-A3E8-99A43A4759F6 Q28080262-AA7F92BC-AC6A-4647-A711-A51E917DD644 Q30318566-902EABEE-907F-4FCB-98D7-918ABC6B358D Q33714400-C248714A-53F2-4CF0-AF5A-AAEFB591F231 Q33726199-06CFD15D-C48C-40C0-A220-D33B99D1C89B Q33820300-FE595DDE-5649-48FB-AB40-2FA476F16CD4 Q33877397-4BADC8AC-66BA-45CA-84F7-3C3493C495B7 Q33886261-25D8CFF1-D6C4-45C1-99A5-14053C6891A4 Q33921487-1553D091-F9B5-49DA-BDA7-2AEC0C194E3E Q34409830-7FF63934-9827-4CD9-AD41-9BF0B94F579B Q34755217-026D0A8A-B049-4702-9E72-B26DA2C409AD Q34916497-49EA41AD-28EC-40DF-8702-CEFBAF8DFA76 Q35005484-005CCE1E-868D-48CB-89F3-482A2374E5FD Q35034710-121E0FF5-A5DB-4D8B-9DD1-08A32F56ACA4 Q35176307-9A01EA66-86A7-4464-AC83-F62159390279 Q35821404-B1FE5643-F7ED-4AEF-813F-DB7D85679937 Q36093456-4E64DFFE-F5E1-43AD-A992-CB558071990A Q36218547-FB7071A5-2841-450E-B911-1DD8298DB6CA Q36866151-400E2676-9A03-45F0-835B-D2B2E203FB4A Q37259624-340677D1-66DC-40C1-90DD-4B93B61413E7 Q37309247-EE3E5432-EA50-40D2-A85C-B5398F06A925 Q37395354-E24B3D58-0D57-4375-95FF-7CEC60F5DAFF Q37499721-3962C10D-40B5-48F2-8323-959404CC6953 Q37621566-C17232B5-1C96-4BBF-ADAF-3B8D0D031049 Q37687418-85C686A9-AD0D-4840-9CBD-3EB5CD35AC3E Q37693733-DC9277D4-CBF4-4FA4-8C7B-46B5646C088A Q37718447-F4CE4B92-AA0E-461D-ABA3-EC9F9AA22061 Q37773259-2D568111-5156-4E9E-8C34-4FD621CE39C5 Q37862064-968AE49F-8611-408B-9DD0-13577A3E5FE5 Q37970674-441D673B-3141-427E-9ABC-0265B08BFB69 Q38000520-93265EF3-EA92-4838-A48D-335E4E649F89 Q38029631-784510B0-3819-4E9B-B491-88BA05CC7F1A Q38043924-2FAFF00A-FD44-4D60-9A26-843FE3E54C86 Q38059514-7CC978A2-D849-4A41-AE6A-0DF1FFD4E7E4 Q38059516-E8922B42-4B94-4410-8551-5B0ADD7E8426 Q38060734-E9CDA9F8-EEE7-40A4-B61C-08B763D22C2E Q38071900-358E32CB-C9B9-40F7-99D0-6F0C4DE8A665

P2860

Current approaches in dendritic cell generation and future implications for cancer immunotherapy.

http://www.wikidata.org/entity/Q36822028

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Current approaches in dendriti ...... ions for cancer immunotherapy.

@en

type

label

Current approaches in dendriti ...... ions for cancer immunotherapy.

@en

prefLabel

Current approaches in dendriti ...... ions for cancer immunotherapy.

@en

P1433

Q36822028-F98A7824-239E-4D19-8ADA-67DC1B0C748F

P1476

Q36822028-9A3FDE8A-4C5C-400F-96C4-CB9F3B6E1036

P2093

Q36822028-0841AAE7-077F-4090-9C95-DEFE3705236F

Q36822028-15F1EFF5-F119-4368-AABB-D4400FB4E3BE

Q36822028-3147F1EE-2EF5-4601-8E45-8AA155230AD8

Q36822028-36A89934-3C2B-4DFA-87E0-E8E288DF753F

Q36822028-4DAB2C96-A6B2-4DF9-87FD-FA68E04B9F6C

Q36822028-B7D070AD-CC63-46C0-AE96-DF971C97DC6D

Q36822028-BD8362E6-0418-4FE1-8310-B3CB8FE18283

Q36822028-EF31D5E4-C575-482D-8CCC-7D0B0F9BAAD2

P2860

Q36822028-03243173-329D-44B6-BF34-B5AB91072F1F

Q36822028-051C87B2-0C66-4E8E-B8C8-9AEA58C79C56

Q36822028-3718FE4D-E11A-491D-9000-D7C386EE7DBC

Q36822028-7C9E8AEC-EF8B-47DA-A65D-1940A3F8B526

Q36822028-95D88DB4-BE4C-405F-8AA7-A13C5CF25639

Q36822028-B346FEAB-8240-468F-8F4A-C278E9C0925A

Q36822028-B713F958-74D5-4590-9B1C-7023E6328604

Q36822028-B882DF2B-74EC-4B82-9BEA-9E0FFBAE2B13

Q36822028-C215FAB8-800A-405D-ABDD-BD6414BA40AE

Q36822028-D4A4A37D-A275-4C25-99B4-F6DBDC5F0C45

P2888

Q36822028-0FAA1D13-E8CD-4043-82D5-72F2277BB0CA

P304

Q36822028-D0D270DC-1D42-48A2-85B1-0C1624475066

P31

Q36822028-57504BBC-32B4-48CF-82BF-A1C3798A562F

P356

Q36822028-256D3B0C-40B2-49A4-A038-4DE02E6E3FCF

P433

Q36822028-460892C2-8EC1-478C-8E49-27926BB347A0

P478

Q36822028-0CD9D9A6-7878-4EEA-A091-2E70BE567EDE

P577

Q36822028-A66F1EEF-361E-4963-9245-5A1C21078809

P5875

Q36822028-62B0CE06-609B-4FB3-A827-01620B7E1A64

P698

Q36822028-3459B5FF-22E9-438B-A0FC-6E7A2AD6188F

P921

Q36822028-F4B92494-D16B-4781-A394-2375F6A5579A

P356

S00262-007-0334-Z

P1433

Cancer Immunology, Immunotherapy

P1476

Current approaches in dendriti ...... ions for cancer immunotherapy.

@en

P2093

Aude Bonehill

http://www.w3.org/2001/XMLSchema#string

Bart Neyns

http://www.w3.org/2001/XMLSchema#string

Carlo Heirman

http://www.w3.org/2001/XMLSchema#string

Joeri L Aerts

http://www.w3.org/2001/XMLSchema#string

Jurgen Corthals

http://www.w3.org/2001/XMLSchema#string

Karine Breckpot

http://www.w3.org/2001/XMLSchema#string

Kris Thielemans

http://www.w3.org/2001/XMLSchema#string

Sandra Tuyaerts

http://www.w3.org/2001/XMLSchema#string

P2860

Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity.

Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.

Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.

Role of cross-talk between IFN-alpha-induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens.

Mannose receptor targeting of tumor antigen pmel17 to human dendritic cells directs anti-melanoma T cell responses via multiple HLA molecules.

Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.

Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation.

IFN-alpha skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities.

Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells.

Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides.

P2888

s00262-007-0334-z

P304

1513-1537

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-007-0334-Z

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2007-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6329363

http://www.w3.org/2001/XMLSchema#string

P698

17503040

http://www.w3.org/2001/XMLSchema#string

P921